BioCryst Pharmaceuticals, Inc.
BioCryst develops oral small-molecule and protein therapeutics for rare diseases. It markets peramivir injection under RAPIVAB, RAPIACTA, and PERAMIFLU names to treat acute uncomplicated influenza. ORLADEYO treats hereditary angioedema. The company also develops BCX10013, an oral factor D inhibitor for complement-mediated diseases. BioCryst has collaborations with various companies and institutions. Founded in 1986, the company is headquartered in Durham, North Carolina.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (52.35) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (14.71%).
- EV/EBITDA (185.55) is significantly higher than the sector mean (51.86).
- EV/EBIT (215.83) is significantly higher than the sector mean.
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (2.98%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 187.3 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 52.3 |